The Weekly Summary

345January 18th – January 24th 2016

In the general news, the stock markets crashed again on Wednesday. Also, an epic snowstorm dumped feet of snow from DC to Boston. However, it was not technically a blizzard due to the low winds.

In healthcare business news, things were slow ahead of earnings. JNJ laid off 6% (3,000 people) of the medical device workforce. Also, UnitedHealth (UNH) raised its estimate for losses in the Obamacare exchange policies they sell.

On the data front, Alkermes (ALKS) depression drug ALKS 5461 failed, sending shares down. Also, Zafgen (ZFGN) obesity drug beloranib met endpoints.

From the FDA, AbbVie (ABBV) and Roche’s cancer drug venetoclax was awarded “breakthrough” status. Lastly, Novartis’ (NVS) Arzerra was approved to treat CLL.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.